KFAS
TGTX icon

Keating Financial Advisory Services’s TG Therapeutics TGTX Stock Holding History

Keating Financial Advisory Services’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4K Hold
189
– – ﹤0.01% 1230
2026
Q1 		$6.28K Buy
189
+144
+320% +$4.29K ﹤0.01% 1320
2025
Q4 		$1.34K Buy
+45
New +$1.47K ﹤0.01% 1714

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Keating Financial Advisory Services's TGTX Position: Q2 2026 in Review

Keating Financial Advisory Services held its TG Therapeutics (TGTX) position steady in Q2 2026 at 189 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1230.

Keating Financial Advisory Services first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Keating Financial Advisory Services held 189 shares of TG Therapeutics worth $10.4K as of Q2 2026.
  • Keating Financial Advisory Services left its TG Therapeutics share count unchanged in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1230 holding.
  • Keating Financial Advisory Services first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.